avutometinib (VS-6766) and adagrasib

Phase 2

Verastem, Inc. (VSTM)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

9 competitors in Non Small Cell Lung Cancer

SNYoxaliplatine / gemcitabine / Vinorelbine

Drug Information

Target Indication

Non Small Cell Lung Cancer

Clinical Trial

NCT05375994

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VSTM

Verastem, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

avutometinibPhase 3

Low Grade Serous Ovarian Cancer

avutometinib (VS-6766)Phase 2

Low Grade Ovarian Serous Adenocarcinoma

avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelPhase 2

KRAS Activating Mutation

Avutometinib (VS-6766) + Defactinib (VS-6063)Phase 2

Low Grade Serous Ovarian Cancer

VS-7375Phase 2

Pancreatic Ductal Adenocarcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts